Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.73 |
| ▸ | MAOB | P27338 | 1/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 9/20 | 0.55 |
| ▸ | CA2 | P00918 | 9/20 | 0.55 |
| ▸ | CA12 | O43570 | 6/20 | 0.55 |
| ▸ | CA9 | Q16790 | 6/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31747379 | 1.00 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL19243360 | 1.00 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL22511877 | 1.00 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL7977069 | 1.00 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL1930913 | 1.00 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL31169524 | 1.00 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL31169526 | 1.00 | MAOA (0.73) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL963880 | 0.98 | MAOA (0.71) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL14086303 | 0.94 | MAOA (0.66) | MAOAMAOBTDP1MEN1GAA | |
| SCHEMBL4967290 | 0.93 | MAOA (0.68) | MAOAMAOBTDP1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4667467-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | Dark Blue Therapeutics Ltd (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-8058262-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-7956059-B2 | Aliphatic amide and ester pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090227594-A1 | ALIPHATIC AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. | 2009-09-10 | — | — | US | disclosed |
| EP-1658255-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-02-18 | — | — | EP | disclosed |
| US-7223745-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1658255-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20050059636-A1 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005016859-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | PSMB11, PSMB5, PSMB6 | MAOA 2808/4885MAOB 2412/4885TDP1 1150/4885 |
| US-20090227594-A1 | ALIPHATIC AMIDE & ESTER PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | KCNH2, CACNA1B, SCNN1G | MAOA 1133/4885MAOB 641/4885TDP1 4603/4885 |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | MAOA 2808/4885MAOB 2412/4885TDP1 1150/4885 |
| US-20050059636-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | MAOA 2808/4885MAOB 2412/4885TDP1 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.